Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response

Table 1 Clinical characteristics of patients with either of two pathological subtypes

Characteristic	All cases (n = 52)	HGSOC (n = 43)	EEOC (n = 9)	P-value	Effect size
Age, median (range), years	56 (34–80)	54 (34–80)	62 (42–76)	0.3593	0.34
Stage, %
I-II	7	4 (9.30%)	3 (33.33%)	0.0900	1.00
III-IV	45	39 (90.70%)	6 (66.67%)	0.0900	1.00
Pre_CA125, median (range), IU/ml	715.5 (20.6–6611.0)	748.0 (20.6–6611.0)	430.9 (220.7–1902.0)	0.4173	0.18
PFS, median (range), months		20 (2–44)	undefined (3–43)	0.5230
Recurrence, %
Recurrence	24	20 (46.51%)	4 (44.44%)	> 0.9999	1.00
No recurrence	28	23 (53.49%)	5 (55.56%)	> 0.9999	1.00
Treated with PARP inhibitor, %
Yes	21	20 (46.51%)	1 (11.11%)	0.0670	1.00
No	31	23 (53.49%)	8 (88.89%)	0.0670	1.00
Surgical excision, %
CRS (R0)	28	21 (48.84%)	7 (77.78%)	0.3366	1.00
CRS (R1)	22	20 (46.51%)	2 (22.22%)
CRS (R2)	2	2 (4.65%)	0 (0.00%)

Footnote: HGSOC, high-grade serous ovarian cancer. EEOC, endometrioid epithelial ovarian cancer. Pre_CA125, preoperative serum carbohydrate antigen 125 values. PFS, progression-free survival. PARP, poly ADP-ribose polymerase. CRS, cytoreductive surgery. R0, no macroscopic residual disease. R1, 1–10 mm residuals. R2, > 10 mm residuals. Statistics in Age: unpaired t test; Statistics in Pre_CA125: Mann–Whitney U test; Statistics in Stage, Recurrence, Treated with PARP inhibitor and Surgical excision: Fisher’s exact test; Statistics in PFS: Log-rank test

ISSN: 1757-2215